Attached files
| file | filename |
|---|---|
| EX-99.1 - PHARMACYCLICS INC | ex991to8k207380_06162012.htm |
| EX-99.2 - PHARMACYCLICS INC | ex992to8k207380_06162012.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2012
|
PHARMACYCLICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
94085-4521
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
On June 16, 2012, multiple presentations were made about Pharmacyclics, Inc.’s (the “Company”) Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), at the 17th Congress of European Hematology Association. At the conference, presentations entitled “The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study” and “Combination of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) with BR Is Active and Tolerable in Patients with Relapsed or Refractory (R/R) CLL/SLL: Interim Results of a Phase Ib/II Study” were presented. Copies of each of the presentations are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Presentation entitled The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study.
|
|
|
99.2
|
Presentation entitled Combination of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) with BR Is Active and Tolerable in Patients with Relapsed or Refractory (R/R) CLL/SLL: Interim Results of a Phase Ib/II Study.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
June 16, 2012
|
PHARMACYCLICS, INC.
|
|||
|
By:
|
/s/ Rainer M. Erdtmann
|
||
|
Name:
|
Rainer M. Erdtmann
|
||
|
Title:
|
Vice President, Finance & Administration and Secretary
|
||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
99.1
|
Presentation entitled The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study.
|
|
99.2
|
Presentation entitled Combination of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) with BR Is Active and Tolerable in Patients with Relapsed or Refractory (R/R) CLL/SLL: Interim Results of a Phase Ib/II Study.
|